Shih-Hsin Chen1, Hung-Ming Wang2, Chien-Yu Lin3, Joseph Tung-Chieh Chang3, Chia-Hsun Hsieh2, Chun-Ta Liao4, Chung-Jan Kang4, Lan-Yan Yang5, Tzu-Chen Yen6. 1. Department of Nuclear Medicine, Chang-Gung Memorial Hospital, Linkou, 5, Fu-Shin St., Kwei-Shan Township, TaoYuan County, Taiwan, 333. 2. Division of Hematology/Oncology, Department of Internal Medicine, Chang-Gung Memorial Hospital, Linkou, 5, Fu-Shin St., Kwei-Shan Township, TaoYuan County, Taiwan, 333. 3. Department of Radiation Oncology, Chang-Gung Memorial Hospital, Linkou, 5, Fu-Shin St., Kwei-Shan Township, TaoYuan County, Taiwan, 333. 4. Departments of Otorhinolaryngology, Head and Neck Surgery, Chang-Gung Memorial Hospital, Linkou, 5, Fu-Shin St., Kwei-Shan Township, TaoYuan County, Taiwan, 333. 5. Clinical Trial Center, Chang-Gung Memorial Hospital, Linkou, 5, Fu-Shin St., Kwei-Shan Township, TaoYuan County, Taiwan, 333. 6. Department of Nuclear Medicine, Chang-Gung Memorial Hospital, Linkou, 5, Fu-Shin St., Kwei-Shan Township, TaoYuan County, Taiwan, 333. yen1110@adm.cgmh.org.tw.
Abstract
BACKGROUND/AIM: We prospectively investigated the potential usefulness of PET using a new tracer targeting integrin αvβ3 (termed RGD-K5) in patients with head and neck cancer (HNC) undergoing definitive concurrent chemoradiotherapy (CCRT). PATIENTS AND METHODS: Newly diagnosed patients with locally advanced HNC scheduled for definitive CCRT were eligible. RDG-K5 PET and FDG PET scans were performed at three different time points (baseline, 2 weeks, and 3 months post-treatment). RESULTS: Nine patients completed all of the three scans, whereas two patients withdrew after two scans only. Uptake of both RGD-K5 and FDG generally decreased following CCRT. However, the observed decrease did not differ significantly between complete responders and non-responders. At 3 months post-treatment, the uptake of both RGD-K5 and FDG at the main tumors was significantly lower in those who achieved complete responses than in those with residual tumors. CONCLUSION: RGD-K5 PET has the potential to identify patients with incomplete responses to CCRT.
BACKGROUND/AIM: We prospectively investigated the potential usefulness of PET using a new tracer targeting integrin αvβ3 (termed RGD-K5) in patients with head and neck cancer (HNC) undergoing definitive concurrent chemoradiotherapy (CCRT). PATIENTS AND METHODS: Newly diagnosed patients with locally advanced HNC scheduled for definitive CCRT were eligible. RDG-K5 PET and FDG PET scans were performed at three different time points (baseline, 2 weeks, and 3 months post-treatment). RESULTS: Nine patients completed all of the three scans, whereas two patients withdrew after two scans only. Uptake of both RGD-K5 and FDG generally decreased following CCRT. However, the observed decrease did not differ significantly between complete responders and non-responders. At 3 months post-treatment, the uptake of both RGD-K5 and FDG at the main tumors was significantly lower in those who achieved complete responses than in those with residual tumors. CONCLUSION: RGD-K5 PET has the potential to identify patients with incomplete responses to CCRT.
Entities:
Keywords:
CCRT; FDG; Head and neck cancer; Integrin αvβ3; PET; RGD-K5
Authors: Samantha Y A Terry; Keelara Abiraj; Jasper Lok; Danny Gerrits; Gerben M Franssen; Wim J G Oyen; Otto C Boerman Journal: J Nucl Med Date: 2014-10-27 Impact factor: 10.057
Authors: Svetlana N Rylova; Enikö Barnucz; Melpomeni Fani; Friederike Braun; Martin Werner; Silke Lassmann; Helmut R Maecke; Wolfgang A Weber Journal: J Nucl Med Date: 2014-10-02 Impact factor: 10.057
Authors: A Argiris; A P Kotsakis; T Hoang; F P Worden; P Savvides; M K Gibson; R Gyanchandani; G R Blumenschein; H X Chen; J R Grandis; P M Harari; M S Kies; S Kim Journal: Ann Oncol Date: 2012-08-16 Impact factor: 32.976
Authors: Matthew G Fury; Nancy Y Lee; Eric Sherman; Donna Lisa; Katherine Kelly; Brynna Lipson; Diane Carlson; Hilda Stambuk; Sofia Haque; Ronglai Shen; Dennis Kraus; Jatin Shah; David G Pfister Journal: Cancer Date: 2012-03-13 Impact factor: 6.860
Authors: Inês Sofia Vala; Leila R Martins; Natsuko Imaizumi; Raquel J Nunes; José Rino; François Kuonen; Lara M Carvalho; Curzio Rüegg; Isabel Monteiro Grillo; João Taborda Barata; Marc Mareel; Susana Constantino Rosa Santos Journal: PLoS One Date: 2010-06-21 Impact factor: 3.240
Authors: Ezra E W Cohen; Darren W Davis; Theodore G Karrison; Tanguy Y Seiwert; Stuart J Wong; Sreenivasa Nattam; Mark F Kozloff; Joseph I Clark; Duen-Hwa Yan; Wen Liu; Carolyn Pierce; Janet E Dancey; Kerstin Stenson; Elizabeth Blair; Allison Dekker; Everett E Vokes Journal: Lancet Oncol Date: 2009-02-07 Impact factor: 41.316
Authors: Daphne Lobeek; Gerben M Franssen; Michelle T Ma; Hans-Jürgen Wester; Clemens Decristoforo; Wim J G Oyen; Otto C Boerman; Samantha Y A Terry; Mark Rijpkema Journal: J Nucl Med Date: 2018-04-06 Impact factor: 10.057
Authors: Ingrid J G Burvenich; Sagun Parakh; Adam C Parslow; Sze Ting Lee; Hui K Gan; Andrew M Scott Journal: AAPS J Date: 2018-03-08 Impact factor: 4.009
Authors: Steve Durante; Vincent Dunet; François Gorostidi; Periklis Mitsakis; Niklaus Schaefer; Judith Delage; John O Prior Journal: EJNMMI Res Date: 2020-05-07 Impact factor: 3.138
Authors: D Lobeek; M Rijpkema; S Y A Terry; J D M Molkenboer-Kuenen; L Joosten; E A J van Genugten; A C H van Engen-van Grunsven; J H A M Kaanders; S A H Pegge; O C Boerman; W L J Weijs; M A W Merkx; C M L van Herpen; R P Takes; E H J G Aarntzen; W J G Oyen Journal: Eur J Nucl Med Mol Imaging Date: 2020-03-20 Impact factor: 9.236